Evaluation of the effect of carvedilol in patients with gastrointestinal cancer

Phase 3

Recruiting

• Conditions: Malignant neoplasm of stomach; Gastrointestinal cancers (Esophageal cancer, Gastric cancer, Pancreatic cancer, Colon cancer).

• Registration Number: IRCT20200907048646N1
• Lead Sponsor: Ardabil University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 6 October 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

All gastrointestinal cancer patients in the age range of 18 to 80 years old underwent 5FU therapy.
LVEF (left ventricular Ejection Fraction)>50%

Exclusion Criteria

Patients with IHD (history of PCI, CABG, and Plavix consumption )
Mitral stenosis and cardiomyopathy
ECG changes characteristic to ischemia (ST-elevation more than 0.5mm and ST-depression more than 1 mm)
Acute myocardial ischemia at any stage of the study (ECG changes characteristic to ischemia, increased cardiac enzymes, or ischemic manifestations on echocardiography).

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Percentage of patients with gastrointestinal cancer with cardiac complications. Timepoint: Evaluation of the patient's cardiac condition before the intervention and during chemotherapy at the end of all 3 courses. Method of measurement: ECG, Troponin, Echocardiography.